Soo Ee Lin on Muck Rack

Soo Ee Lin

As seen in: Mondaq
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Soo Ee

Contact Soo Ee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Insights from APAA 2024

|
By Soo Ee Lin, Kua Han Chun, Ayesha Lee, Jon Wright
| Mondaq
Hosted at the SMX Convention Center and Conrad Hotel in Pasay City, the event provided an invaluable opportunity for collaboration, knowledge-sharing, and networking, highlighting the collective expertise and commitment to advancing the IP field. As a firm supporter of both APAA and its key annual event, Spruson & Ferguson participates every year.
Open in Who Shared Issue with article?

Practice Note: What to do with medical use claims when employing the Foreign Route of patent prosecution in Singapore

|
By Soo Ee Lin
| Mondaq
Singapore: Practice Note: What to do with medical use claims when employing the Foreign Route of patent prosecution in Singapore To print this article, all you need is to be registered or login on Mondaq.com. Patent Law in India The Patents Act 1970, along with the Patents Rules 1972, came into force on 20th April 1972, replacing the Indian Patents and Designs Act 1911. The Patents Act was largely based on the recommendations of the Ayyangar Committee Report headed by Justice N.
Open in Who Shared View Duplicates (4) Issue with article?

Protection of Second and Subsequent Medical Use in Singapore

|
By Natsuho Yamamoto, Soo Ee Lin
| Lexology Verified
In Singapore, second and subsequent medical use of a known substance has traditionally been claimed as Swiss-style claims which take the form of “Use of compound X in the manufacture of a medicament for treating disease Y”. Recently, two court cases (Warner-Lambert Company v Novartis (Singapore) [2016] SGHC 106 and Warner-Lambert Company v Novartis (Singapore) [2017] SGCA 45) have shed some light, for the first time in Singapore, on how these claims are to be treated.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified